ANIX vs PATH · rev $210.0K vs P/E 19, rev $1.61B
Anixa Biosciences Inc (ANIX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Anixa Biosciences Inc (ANIX) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ANIX revenue for 2024-10-31 was $210.0K. Net income was -$12.7M. Revenue was up 0.0% from 2023-10-31 to 2024-10-31. ANIX currently screens at market cap $101.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ANIX currently screens at market cap $101.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ANIX and PATH stock pages for the full models.
Not investment advice.